title: [The cytochemical characteristics of neutrophilic leukocytes in the peripheral blood and synovial fluid of patients with rheumatoid arthritis in the course of treatment].
abstract: The authors studied the activity of alkaline and acid phosphatase (AP), myeloperoxidase (MP), the level of cationic protein (CP), spontaneous and pyrogenal-induced tests of restoration of nitroblue of tetrazolium (HCT-test) in the blood and synovial fluid (SF) neutrophils in 116 patients with rheumatoid arthritis (RA) in the dynamics of a 3-4-week and subsequent 6-month therapy with chrysanol, salazopyridazine and delagil. In the active phase all the patients exhibited an abrupt increase in the activity of alkaline and acid phosphatase in blood neutrophils, a drop in the level of CP (in 69%), a rise in the activity of MP (in 32%); pyrogenal did not induce any capacity for restoring HCT (in 44%). Indices of alkaline and acid phosphatase in blood and SF neutrophils and also of the induced TCT-test in blood neutrophils correlated with the degree of RA activity. Statistically significant positive cytochemical shifts were noted only after 6 months of treatment: a decrease in alkaline and acid phosphatase activity, a rise in the level of CP, MP and capacity for restoration pf HCT with pyrogenal in blood neutrophils. Increase in the correlation of CP or MP levels by 0.2 or more in blood and SF neutrophils, and also of the normal level of CP in blood neutrophils or its increase not less than by 15% 3-4 weeks after the beginning of therapy evidence good prognostic informativeness with respect to the effectiveness of basic therapy.
authors.forename: A A
authors.initials: AA
authors.lastname: Fisher
authors.forename: A Iu
authors.initials: AIu
authors.lastname: Ionov
authors.forename: M G
authors.initials: MG
authors.lastname: Shubich
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000627:therapeutic use; D018501:Antirheumatic Agents / Q000627:therapeutic use; D001172:Arthritis, Rheumatoid / Q000188:drug therapy* / Q000473:pathology; D002738:Chloroquine / Q000031:analogs & derivatives / Q000627:therapeutic use; D004112:Dimercaprol / Q000627:therapeutic use; D005260:Female; D006801:Humans; D008297:Male; D008667:Metalloproteins / Q000627:therapeutic use; D008875:Middle Aged; D009504:Neutrophils / Q000378:metabolism*; D050607:Organogold Compounds; D009942:Organometallic Compounds; D020005:Propanols; D012460:Sulfasalazine / Q000031:analogs & derivatives / Q000627:therapeutic use; D013438:Sulfhydryl Compounds; D013582:Synovial Fluid / Q000166:cytology*
chemical_list: D000894:Anti-Inflammatory Agents, Non-Steroidal; D018501:Antirheumatic Agents; D008667:Metalloproteins; D050607:Organogold Compounds; D009942:Organometallic Compounds; D020005:Propanols; D013438:Sulfhydryl Compounds; D004112:Dimercaprol; C009943:salazodin; D012460:Sulfasalazine; C023676:chloroquine diphosphate; D002738:Chloroquine; C013394:aurotioprol